Every day, Thomson Reuters touches millions of automobile aficionados around the world, including people who design vehicles, regulate their safety, invest in automakers, provide tax advice to them, sue and defend manufacturers and suppliers, and, in the case of the 2015 Frankfurt Auto Show which is currently underway, marvel at the sleek lines, speed and agility of the concept cars that offer unique and wonderful views of a future of which we all want to be a part. In the next few days we’re running a series of blog posts that will provide glimpses into the professional lives of our customers touching the auto industry, through proprietary data, insights and expert analysis that only Thomson Reuters can deliver.
Nothing captures the imagination of the public faster than a discussion on the car of the future. The driving public have been dreaming about flying cars for decades, and recently Toyota made headlines when a patent application suggesting they were working on one was published. Now in this case US20150246720 describes “an aerocar including a stackable wing and methods for morphing the stackable wing…atop the aerocar,” as opposed to a fully functional flying vehicle, so in reality we are probably many years away from a time when we can fly to work during our daily commute.
Cars that drive themselves were also a part of the automotive dreamscape that is until recent advances, most publicly by Google, demonstrate that the future of autonomous driving may be closer than previously thought. Experts claim the technology is still years away from being viable in all traffic conditions, but that has not stopped Google from conducting field tests, or Apple from apparently speaking with the State of California about autonomous driving regulations. Beyond these news reports, the automotive industry in general has filed a significant number of patents in the autonomous driving field, and Figure 1 shows the trend in autonomous driving patent published by the top six filers in the field over the last three years. (more…)
We’re pleased to announce the latest addition to our Know 360 stable of thought-leadership publications – Thomson Reuters Innovation – a new twice-yearly magazine for science professionals.
Innovation is at the heart of the global economy. It is rooted in our desire to know more about the world, discover its infinite possibilities and find better ways of doing things. The inaugural issue of Thomson Reuters Innovation magazine provides unique insights to compare industries and companies based on patent, scientific and financial information.
This issue takes inspiration from the concept of multiple viewpoints – a new and completely fresh perspective, it crowd-sources through experiences and points of view from across the global science community.
This post is by Helen Walker, Senior Communications Specialist, Thomson Reuters
Over 25 years ago, my mum was diagnosed with breast cancer. Seven months ago she was told she had ovarian cancer. Due to a combination of radical surgery, great healthcare and the fact that she is the most stubborn person I know, mum has made a full recovery from both and is currently sunning herself in Greece.
Mine is not a unique story – most of us know someone affected by cancer or other potentially life changing illnesses. I imagine then, that you might be as fascinated as I was by this piece: When the genes fit: A cancer cure.
While my mum had to go through a mastectomy and removal of her ovaries, the future is different. Better understanding of genes and how they influence disease means that precision medicine – treatment tailored to an individual – can be used to identify the right drugs to treat the disease. And the future is already here; this is already happening in major academic medical centers.
I am one of mum’s three daughters. We have the option through genetic screening to find out if we carry the faulty gene. It’s reassuring to know though, that should one of us end up on the same path as mum, the advances in medicine mean that any diagnosis may not be as catastrophic for us as they were for her.
That explains my personal interest in this article but my other interest is what our role, the role of IP & Science, is in this amazing step in medicine. I asked Wendy Hamilton, Global Head of Life Sciences to help me understand.
What role does Life Sciences have in precision medicine? (more…)
The future of innovation is in our hands.
Up there with leadership and strategy, innovation is one of the most over-used words in business today, throughout the world. I challenge any CEO to define what they mean by innovation. Many don’t seem to understand it. Innovation is too valuable to be misunderstood. It’s time to change that. (more…)
Innovation is the lifeblood of the global economy, and is in its golden age. In the last decade alone, we have witnessed the introduction landmark inventions, from driverless cars, to bionic limb reconstructions, to the discovery of the Higgs Boson. That’s why it may come as a surprise that we’re reporting that year-over-year innovation growth has hit the slowest pace since the global economic recession.
A new study from our IP & Science business finds that the global pace of innovation has slowed to its lowest level since the recession. The study, which analyzes global intellectual property data — including scientific literature and patents – as a window into innovation in 12 bellwether technology areas, suggests a possible inflection point in global R&D growth in both private sector companies and academic research institutions worldwide.
Following are some of the highlights: (more…)
Last week I had the pleasure of presenting findings from a new report into intellectual property (IP) licensing at a World IP Day event in Paris. With 10.8 billion Euros estimated to be generated in the French licensing market alone, the licensing of intellectual property (IP) is a conversation starter for anyone working in the IP industry.
For those less familiar with the subject, the licensing of intellectual property rights is the process whereby an inventor forms a partnership to license IP rights for commercial gain in exchange for a fee. With that, much of the dialogue around the licensing market is taken by those arguing for a change in the law to enhance the market and make it more transparent.
But in the absence of strong data, the arguments put forward are largely based on assumptions and individual experiences so it is important to get the full pictures of the licensing market. (more…)
Perhaps nowhere is the importance of “knowing why” more apparent than in the interplay of world energy markets and the increasing urgency of climate and environmental issues. Today’s graphic, from our 2014 Annual report, overlays the number of renewable energy inventions with price of oil.
Sources: Thomson Reuters Derwent World Patents Index, Thomson Reuters Web of Science and Thomson Reuters Datastream
2014 was a year in which knowing more —who, what, why and how — was critical to informed decision making and successful outcomes. Explore our 2014 Annual Report.
Perhaps nowhere is the importance of “knowing why” more apparent than in the interplay of world energy markets and the increasing urgency of climate and environmental issues. See how through context, connection and insight, we help professionals know why changes are occurring in world energy, identify and develop alternatives, and monitor the environmental impacts of energy: (more…)
Our customers participate in the most important conversations in a fast and complex world every day. As professionals, they navigate markets, risks and regulations; shape and manage legal systems and tax jurisdictions; protect innovations; and drive scientific discovery. Their work is important and their decisions matter. And common to them all is the need to know.
Professionals today need more. More than information, data and news. More than speed. More than mobile access. They need insight, analysis and context. Solutions that simplify, clarify and deliver competitive advantage, providing confidence to act on what they know. And millions of professionals from every part of the global economy rely on Thomson Reuters for what they need to know to understand critical issues, solve tough problems and adapt to dynamic change.
During 2014, the risks of global fraud and rising terrorism; the multi-stage recovery of world markets and the opening up of China; the significant shift in oil prices and increasingly urgent focus on climate change and energy alternatives; and the economic and social impacts of an aging world population and Alzheimer’s disease were just a few of the challenges and opportunities facing our world. It was a year in which knowing more — who, what, why and how — was critical to informed decision making and successful outcomes.
Explore our 2014 Annual Report – Know which includes the Corporate Responsibility & Inclusion and Thomson Reuters Foundation annual reports.
In January 2014, Thomson Reuters Cortellis Competitive Intelligence named three drugs to watch that were expected to enter the market that year and make sales of over $1 billion within five years. All three entered the market as anticipated, and although the Cortellis Consensus sales forecasts have fluctuated over the course of the year, all of the drugs are still forecast to be $1 billion-plus blockbusters.
Compared with 2014, there are more potential blockbusters expected to enter the market this year. The majority of them are forecast to have 2019 sales of between $1 billion and $3 billion, although three drugs are set to exceed this, with the following 2019 sales forecasts: Bristol-Myers Squibb’s (BMS) melanoma drug Opdivo (nivolumab) at $5.684 billion; Regeneron Pharmaceuticals and Sanofi’s Praluent (alirocumab) for hypercholesterolemia at $4.414 billion; and Novartis’ LCZ-696 (sacubitril and valsartan) for chronic heart failure at $3.731 billion: (more…)